{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:42:01Z","timestamp":1793457721902,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Istanbul University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>This study aimed to evaluate the personalized dosimetric approach by calculating the cumulative renal absorbed dose (cRD) and assessing its impact on renal functions in patients diagnosed with metastatic castration-resistant prostate cancer who underwent four or more cycles of [<jats:sup>177<\/jats:sup>Lu] Lu-PSMA \u2212\u2009617 therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The study included 110 patients who received \u2265\u20094 cycles of [<jats:sup>177<\/jats:sup>Lu] Lu-PSMA \u2212\u2009617 therapy. Whole-body static and abdominal SPECT-CT imaging was performed at 4, 24, and 96\u00a0h post-administration. Kidney function was assessed using dynamic renal scintigraphy and biochemical tests conducted prior to treatment. Estimated glomerular filtration rate (eGFR) levels were calculated using the CKD-EPI formula before each treatment cycle and at the 6th week post-treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Pearson correlation analysis reveal no significant relationship between cRD and CKD-EPI values (<jats:italic>p<\/jats:italic>\u2009&gt;.05). No significant differences were observed between pre-treatment CKD-EPI levels and those measured after the 4th, 5th, 6th, 7th, and 8th cycles (<jats:italic>p<\/jats:italic>\u2009&gt;.05). Among patients reaching a cRD of 23\u00a0Gy, a statistically significant difference was observed between pre- and post-treatment CKD-EPI values (<jats:italic>p<\/jats:italic>\u2009&lt;.05). Of the 13 patients exceeding cRD of 28\u00a0Gy, five maintained CKD-EPI levels above 90 mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup> post-treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Despite treatment-related declines in eGFR levels, our findings indicate that a personalized dosimetric approach may enable extended cycles of [<jats:sup>177<\/jats:sup>Lu] Lu-PSMA-617 therapy with manageable nephrotoxicity. Considering the significant inter-patient variability, establishing universal absorbed dose-response relationships remains challenging. Prospective multicenter studies are crucial to refining toxicity thresholds and advancing tailored treatment strategies to optimize safety and efficacy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00259-025-07125-1","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T07:08:48Z","timestamp":1741590528000},"page":"3135-3144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Impact of extended [177Lu] Lu-PSMA-617 therapy on absorbed kidney dose and CKD-EPI values: how long can therapy be safely continued?"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9848-3156","authenticated-orcid":false,"given":"Edanur","family":"Topal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4431-8358","authenticated-orcid":false,"given":"Bilal","family":"Kovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1686-7114","authenticated-orcid":false,"given":"Ayca","family":"\u0130ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1158-5361","authenticated-orcid":false,"given":"Serkan","family":"Kuyumcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5437-134X","authenticated-orcid":false,"given":"Mert","family":"Basaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-0146","authenticated-orcid":false,"given":"Aydan","family":"Mal\u00e7ok Demirta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5801-6898","authenticated-orcid":false,"given":"Oner","family":"Sanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-2379","authenticated-orcid":false,"given":"Yasemin","family":"Sanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"issue":"1","key":"7125_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"7125_CR2","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(10):1067\u201396.","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"7125_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"11","key":"7125_CR4","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","volume":"56","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate Cancer by PET\/CT: Biodistribution in humans, Radiation Dosimetry, and first evaluation of Tumor lesions. J Nucl Med. 2015;56(11):1697\u2013705.","journal-title":"J Nucl Med"},{"issue":"13","key":"7125_CR5","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","volume":"42","author":"L Kabasakal","year":"2015","unstructured":"Kabasakal L, et al. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(13):1976\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7125_CR6","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00259-019-04583-2","volume":"47","author":"J Maffey-Steffan","year":"2020","unstructured":"Maffey-Steffan J, et al. The (68)Ga\/(177)Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up. Eur J Nucl Med Mol Imaging. 2020;47(3):695\u2013712.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"7125_CR7","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.18632\/oncotarget.12240","volume":"8","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2017;8(2):3581\u201390.","journal-title":"Oncotarget"},{"issue":"4","key":"7125_CR8","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00259-021-05538-2","volume":"49","author":"SMB Peters","year":"2022","unstructured":"Peters SMB, et al. [(68)Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [(177)Lu]Lu-PSMA-617 treatment. Eur J Nucl Med Mol Imaging. 2022;49(4):1101\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"7125_CR9","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","volume":"46","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46(12):2536\u201344.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"7125_CR10","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, et al. Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50(9):2830\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7125_CR11","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","volume":"49","author":"K Sj\u00f6green Gleisner","year":"2022","unstructured":"Sj\u00f6green Gleisner K, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49(6):1778\u2013809.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7125_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825\u201333.","journal-title":"Lancet Oncol"},{"issue":"19","key":"7125_CR13","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, et al. New Creatinine- and cystatin C\u2013Based equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737\u201349.","journal-title":"N Engl J Med"},{"issue":"1","key":"7125_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"A Levin","year":"2013","unstructured":"Levin A, et al. Kidney disease: improving global outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Supplements. 2013;3(1):1\u2013150.","journal-title":"Kidney Int Supplements"},{"issue":"4","key":"7125_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, et al. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate Cancer: correlations between Pretherapeutic Imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60(4):517\u201323.","journal-title":"J Nucl Med"},{"issue":"3","key":"7125_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2967\/jnumed.116.178483","volume":"58","author":"S Okamoto","year":"2017","unstructured":"Okamoto S, et al. Radiation Dosimetry for (177)Lu-PSMA I&T in metastatic castration-resistant prostate Cancer: absorbed dose in normal organs and Tumor lesions. J Nucl Med. 2017;58(3):445\u201350.","journal-title":"J Nucl Med"},{"issue":"10","key":"7125_CR17","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","volume":"35","author":"L Bodei","year":"2008","unstructured":"Bodei L, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35(10):1847\u201356.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"7125_CR18","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1007\/s00259-018-4044-x","volume":"45","author":"M Cremonesi","year":"2018","unstructured":"Cremonesi M, et al. Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging. 2018;45(13):2426\u201341.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4 Suppl","key":"7125_CR19","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/cncr.24796","volume":"116","author":"M Garkavij","year":"2010","unstructured":"Garkavij M, et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116(4 Suppl):1084\u201392.","journal-title":"Cancer"},{"issue":"2","key":"7125_CR20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s00259-009-1216-8","volume":"37","author":"M Sandstr\u00f6m","year":"2010","unstructured":"Sandstr\u00f6m M, et al. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging. 2010;37(2):212\u201325.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7125_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40658-021-00385-4","volume":"8","author":"F Rosar","year":"2021","unstructured":"Rosar F, et al. Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy. EJNMMI Phys. 2021;8(1):40.","journal-title":"EJNMMI Phys"},{"issue":"1","key":"7125_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","volume":"43","author":"A Delker","year":"2016","unstructured":"Delker A, et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(1):42\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7125_CR23","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7125_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","volume":"21","author":"B Emami","year":"1991","unstructured":"Emami B, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"7125_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2967\/jnumed.112.107524","volume":"54","author":"M Sandstr\u00f6m","year":"2013","unstructured":"Sandstr\u00f6m M, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing\u2009<\u2009sup\u2009>\u2009177\u2009Lu-DOTA-Octreotate treatment. J Nucl Med. 2013;54(1):33\u201341.","journal-title":"J Nucl Med"},{"issue":"15","key":"7125_CR26","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1200\/JCO.23.01241","volume":"42","author":"AP Kiess","year":"2024","unstructured":"Kiess AP, et al. How can Radiopharmaceutical therapies Reach their full potential? Improving dose reporting and phase I clinical Trial Design. J Clin Oncol. 2024;42(15):1734\u20137.","journal-title":"J Clin Oncol"},{"key":"7125_CR27","doi-asserted-by":"crossref","unstructured":"Rosar F et al. Renal safety of [(177)Lu]Lu-PSMA-617 Radioligand Therapy in patients with compromised baseline kidney function. Cancers (Basel), 2021. 13(12).","DOI":"10.3390\/cancers13123095"},{"issue":"8","key":"7125_CR28","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, et al. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-resistant prostate Cancer with 177Lu-Labeled PSMA-617. J Nucl Med. 2016;57(8):1170\u20136.","journal-title":"J Nucl Med"},{"issue":"5","key":"7125_CR29","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s00259-016-3609-9","volume":"44","author":"L Scarpa","year":"2017","unstructured":"Scarpa L, et al. The (68)Ga\/(177)Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUV(max) values and absorbed dose estimates. Eur J Nucl Med Mol Imaging. 2017;44(5):788\u2013800.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6suppl","key":"7125_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1200\/JCO.2022.40.6_suppl.097","volume":"40","author":"K Herrmann","year":"2022","unstructured":"Herrmann K, et al. Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study. J Clin Oncol. 2022;40(6suppl):97\u201397.","journal-title":"J Clin Oncol"},{"issue":"5","key":"7125_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.eururo.2022.05.025","volume":"83","author":"H Sch\u00e4fer","year":"2023","unstructured":"Sch\u00e4fer H, et al. Extensive (177)Lu-PSMA Radioligand Therapy Can lead to Radiation Nephropathy with a renal thrombotic microangiopathy-like picture. Eur Urol. 2023;83(5):385\u201390.","journal-title":"Eur Urol"},{"issue":"11","key":"7125_CR32","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.2967\/jnumed.108.053173","volume":"49","author":"BW Wessels","year":"2008","unstructured":"Wessels BW, et al. MIRD Pamphlet 20: the Effect of Model assumptions on kidney dosimetry and response\u2014implications for Radionuclide Therapy. J Nucl Med. 2008;49(11):1884\u201399.","journal-title":"J Nucl Med"},{"issue":"1","key":"7125_CR33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2967\/jnumed.123.265986","volume":"65","author":"L Steinhelfer","year":"2024","unstructured":"Steinhelfer L, et al. Long-term nephrotoxicity of (177)Lu-PSMA Radioligand Therapy. J Nucl Med. 2024;65(1):79\u201384.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07125-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07125-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07125-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:52:22Z","timestamp":1751435542000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07125-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7125"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07125-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants included in the study. This retrospective study was approved by our institutional review board, and written informed consent was obtained from all patients","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}